Nilo Therapeutics

News

New biotech financings include nine-figure rounds for Soufflé, Expedition, Arthrosi, and Nilo Therapeutics, with NanoPhoria and TORL not far behind.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.